IL6 and COVID-19: Many reports have presented the clinical efficacy of IL-6 blockade in treating ∼1600 severe/critically ill COVID-19 patients using the anti-IL-6R monoclonal antibodies tocilizumab (Alattar et al., 2020; Capra et al., 2020; Guaraldi et al., 2020; Ip et al., 2020; Klopfenstein et al., 2020; Knorr et al., 2020; Morena et al., 2020; Perrone et al., 2020; Rojas-Marte et al., 2020; Toniati et al., 2020; Xu X. et al., 2020), or sarilumab (Benucci et al., 2020), and IL-6 neutralizing antibody siltuximab (Gritti et al., 2020).